The study sought to assess the pharmacodynamic (PD) effects of switching to ticagrelor patients who were treated with prasugrel after undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome.
Switching antiplatelet therapies is a common occurrence in clinical practice (7) . In fact, the current availability of different oral P2Y 12 receptor antagonists allows for multiple treatment options and has indeed raised the question on the optimal approach for switching among these therapies if needed or desired. To date, most studies have been designed to specifically assess the PD effects associated with switching from clopidogrel to either prasugrel or ticagrelor (7) . However, there are limited studies on other switching options that occur in clinical practice, such as those between the newgeneration P2Y 12 receptor inhibitors. In a recent study, switching from ticagrelor to prasugrel was associated with an increase in platelet reactivity and HPR rates, which was suggestive of a drug interaction (8) . Transitioning therapy with the use of a loading dose (LD) of prasugrel rather than with just a maintenance dose (MD) regimen mitigated such increase in platelet reactivity. Indeed, these observations have led to question the PD profiles occurring when switching from prasugrel to ticagrelor as well as the optimal dosing regimen for clinicians to consider when this is required. 
Switching From Prasugrel to Ticagrelor -2 0 1 6 : ---HPR was defined by a PRU >208 as assessed by VN-P2Y12, a PRI >50% as assessed by VASP, or MPA >59% as assessed by LTA following 20 mM ADP stimuli (4) . Because LTA results with 5 mM ADP were consistent with 20 mM ADP, these are reported in the Appendix (Online Figures 1A and B) .
SAMPLE SIZE CALCULATION AND STUDY ENDPOINTS.
The primary hypothesis of our study was that after 1 week of randomized treatment PRU levels would be noninferior in patients switched from prasugrel to ticagrelor (2 arms combined) compared with patients remaining on prasugrel. Noninferiority was assessed using a 95% confidence interval (CI) of the difference in mean PRU between prasugrel and ticagrelor (2 arms Platelet function tests included VerifyNow P2Y12 point-of-care testing, whole blood vasodilator-stimulated phosphoprotein, and light transmittance aggregometry. LD ¼ loading dose; MD ¼ maintenance dose.
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The primary population was defined as patients who received the randomized treatment and had a valid primary endpoint value (PRU at 1 week), and was used for analysis of all PD endpoints. The treated population comprised all patients who received any dose of study medication and was considered for analysis of safety and adverse events. Table 1 ; there were no significant differences among the 3 treatment groups.
RESULTS
PHARMACODYNAMIC FINDINGS. At baseline, while on maintenance prasugrel therapy, there were no significant differences among groups in levels of on-treatment platelet reactivity with all assays: PRU
FIGURE 2 Subject Disposition
The treated population (n ¼ 82) comprised all randomized patients who received any dose of study medication and was considered for safety analysis. The primary population (n ¼ 79) was defined as patients who received the randomized treatment and had valid primary endpoint data (P2Y 12 reaction units at 1 week), and was used for analysis of all pharmacodynamic endpoints.
Switching From Prasugrel to Ticagrelor HPR rates varied according to the assay used ( Table 2 ). In particular, at baseline, HPR rates reflecting trough levels of platelet reactivity induced by maintenance prasugrel therapy were 1.3%, 26.6%, and 6.3% as assessed by PRU, PRI, and MPA. After randomization, there were no patients with HPR as defined by PRU at all study time points with the exception of 2 patients at 1 week, who both received ticagrelor. Rates of HPR as assessed by PRI were overall higher; following randomization, HPR rates decreased with both prasugrel and ticagrelor, although these were more markedly reduced with ticagrelor, leading to significant differences between groups at 4, 24, and 48 h, but not at 1 week. HPR rates assessed by MPA were similar to those defined by PRU.
DISCUSSION
The SWAP-3 study is the first prospective, randomized study to assess the PD effects of switching from prasugrel to ticagrelor. In particular, we demonstrated that transitioning to ticagrelor patients who were on standard of care maintenance treatment with prasugrel, on a background of aspirin, following PCI in the setting of an ACS, was associated with a 
Franchi et al. Error bars represent 95% confidence interval. MPA ¼ maximal platelet aggregation.
Switching From Prasugrel to Ticagrelor Overall, the availability of 3 oral P2Y 12 receptor inhibitors makes switching amongst these therapies common in clinical practice (7) . In a recent study, a reduction in platelet reactivity and HPR rates was shown 30 days after switching to ticagrelor patients with HPR while on prasugrel (13) . However, to date, the early PD profiles of transitioning patients from prasugrel to ticagrelor, as well as the differential effects of switching with or without a LD, had not been explored. In clinical practice, several reasons may prompt a switch from prasugrel to ticagrelor.
These include both patient and physician preference as a result of drug access (e.g., depending on health care system or medical insurance) and ticagrelor's mortality benefit during the first year after an ACS (6).
The recent demonstration of ischemic benefits, albeit at the expense of increased bleeding, associated with prolonging ticagrelor therapy beyond 1 year post-ACS may also be a reason to switch from prasugrel to ticagrelor (14) . Moreover, data from real-world clinical practice show that some patients may be treated with prasugrel, despite having a contraindication, and may be candidates for ticagrelor therapy. These include ACS patients who get pretreated with prasugrel prior to defining coronary anatomy but do not undergo PCI or those who have a prior cerebrovascular event (15, 16) .
The need to define how to transition from prasugrel to ticagrelor treatment is underscored by prior studies demonstrating drug interactions and inadequate platelet inhibition when switching between different classes of P2Y 12 receptor inhibitors (i.e., thienopyridines and nonthienopyridines) (7, 8, 17, 18) .
The potential clinical implications of an increase in platelet reactivity and HPR rates are noteworthy, as this may expose patients to an increased risk of a thrombotic complication, particularly patients who Tinted area indicated zone of noninferiority. The dotted line represents the pre-specified limit of noninferiority of þ45.
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Switching From Prasugrel to Ticagrelor STUDY LIMITATIONS. It may be argued that switching patients from prasugrel to ticagrelor was associated with enhanced platelet inhibition and that low platelet reactivity has been associated with bleeding complications (4, 19) . However, significant reductions in platelet reactivity were limited to the first 48 h after switching, and we did not observe any major bleeding complications. Nevertheless, our study was not powered to make any safety conclusions. Because of our study design, some residual effect of prasugrel may have still been present up to 7 days (22). Indeed, prolonging the study would have allowed for complete recovery from prasugrel exposure and thus provided information on the comparative PD efficacy between the 2 agents. However, this was not the intent of our study design. In fact, the PD measurements at 7 days were assessed to rule out any drug interaction beyond the first 24 to 48 h and should not be considered to compare the PD efficacy between prasugrel and ticagrelor, which was the objective of other reported investigations (11, 23) . Ultimately, we studied the PD effect of switching to ticagrelor patients who were on a MD regimen of prasugrel. Thus we cannot extrapolate our findings to patients who had just received a prasugrel LD, although our observations would not suggest that this would be associated with a drug interaction.
CONCLUSIONS
In patients on maintenance treatment with prasugrel, on a background of aspirin, switching to ticagrelor therapy led to transiently higher levels of platelet inhibition. These PD findings were observed in the early Switching from ticagrelor to prasugrel is associated with a drug interaction leading to increased platelet reactivity.
WHAT IS NEW? Switching patients from prasugrel to ticagrelor is associated with transiently higher levels of platelet inhibition and no drug interactions. Switching can be performed using a standard 90 mg bid ticagrelor maintenance dose regimen, without the need for a loading dose.
WHAT IS NEXT? Prospective clinical studies are needed to define the safety of this strategy on bleeding and thrombotic outcomes. 
